| Date | Title | Description |
| 28.03.2025 | Saniona’s CSO to BioStock: “We are on track with SAN2219” | Saniona’s CSO to BioStock: “We are on track with SAN2219”
Fri, Mar 28, 2025 08:46 CET Report this content
Saniona has taken a step forward within its epilepsy program by initiating the scale-up and manufacturing of toxicology batches for SA... |
| 26.03.2025 | Saniona’s CEO to BioStock: “The TO4 proceeds give us flexibility to secure the best deals” | Saniona’s CEO to BioStock: “The TO4 proceeds give us flexibility to secure the best deals”
Wed, Mar 26, 2025 09:09 CET Report this content
Saniona has secured guarantee commitments for its ongoing TO4 warrant exercise, running from March 18... |
| 12.03.2025 | Saniona’s new CMO to BioStock: “More deals are definitely on the horizon” | Saniona’s new CMO to BioStock: “More deals are definitely on the horizon”
Wed, Mar 12, 2025 11:49 CET Report this content
Saniona has appointed Pierandrea Muglia, M.D., as Chief Medical Officer, bringing over three decades of expertise from... |
| 07.03.2025 | BioStock: Saniona’s CEO comments on the recent news | BioStock: Saniona’s CEO comments on the recent news
Fri, Mar 07, 2025 09:25 CET Report this content
Saniona is advancing its treatments for epilepsy and neurological disorders, with SAN2355 – a selective epilepsy therapy – now in GMP-manufa... |
| 06.03.2025 | Qlife's Strategic Expansion: A Bold Move in the Biotech Arena | In the ever-evolving landscape of biotechnology, Qlife is making waves. The Swedish company, based in Göteborg, is on a mission to revolutionize home diagnostics. With its innovative platform, Egoo.Health, Qlife aims to provide lab-quality ... |
| 04.03.2025 | Notice of Extraordinary General Meeting 2025 in Qlife Holding AB | Notice of Extraordinary General Meeting 2025 in Qlife Holding AB
Tue, Mar 04, 2025 10:40 CET Report this content
Qlife Holding AB, reg.no. 559224-8040 (the ”Company”), will hold an Extraordinary General Meeting on 21 March 2025 at. 10.00 at... |
| 04.03.2025 | Qlife reaffirms its strategy and plans to expand the Board with three new members | Qlife reaffirms its strategy and plans to expand the Board with three new members
Tue, Mar 04, 2025 10:45 CET Report this content
Following a successful rights issue, Qlife has convened an extraordinary general meeting to expand its Board o... |
| 28.02.2025 | BioStock: Saniona strengthened its cash position and advanced through partnership | BioStock: Saniona strengthened its cash position and advanced through partnership
Fri, Feb 28, 2025 09:54 CET Report this content
Saniona’s key milestone in 2024 was securing an exclusive worldwide licensing agreement with Acadia Pharmaceut... |
| 24.02.2025 | BioStock: Saniona’s CEO responds to investors’ questions | BioStock: Saniona’s CEO responds to investors’ questions
Mon, Feb 24, 2025 10:30 CET Report this content
Saniona’s collaboration with Acadia Pharmaceuticals, signed in November, marked a significant milestone for the company. With a total p... |
| 10.02.2025 | Live interview with Saniona tomorrow – submit your questions! | Live interview with Saniona tomorrow – submit your questions!
Mon, Feb 10, 2025 11:10 CET Report this content
Saniona made the headlines late last year when the company entered a partnership with Acadia Pharmaceuticals, a deal worth up to 6... |
| 16.01.2025 | BioStock: Saniona-backed Cephagenix secures 9 MEUR in seed financing | BioStock: Saniona-backed Cephagenix secures 9 MEUR in seed financing
Thu, Jan 16, 2025 11:23 CET Report this content
Saniona has announced that Cephagenix, a joint venture with Professor Jes Olesen at the University of Copenhagen, has succe... |
| 12.11.2024 | BioStock: Saniona provided a tesofensine update | BioStock: Saniona provided a tesofensine update
Tue, Nov 12, 2024 15:26 CET Report this content
Last week, Saniona announced that its partner Medix in Mexico had not received regulatory approval for tesofensine. In a new update, Saniona cla... |
| 15.10.2024 | BioStock: Saniona achieves milestone with Boehringer Ingelheim | BioStock: Saniona achieves milestone with Boehringer Ingelheim
Tue, Oct 15, 2024 11:19 CET Report this content
Saniona’s collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research... |
| 08.10.2024 | BioStock: Saniona has started dosing in the SAN711 trial | BioStock: Saniona has started dosing in the SAN711 trial
Tue, Oct 08, 2024 08:31 CET Report this content
Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release ... |
| 03.10.2024 | Saniona’s CEO to BioStock: “SAN2355 is a highly promising candidate for commercialization” | Saniona’s CEO to BioStock: “SAN2355 is a highly promising candidate for commercialization”
Thu, Oct 03, 2024 09:45 CET Report this content
Saniona has announced significant progress in the preclinical development of the epilepsy drug candid... |
| 19.09.2024 | BioStock: Saniona comments on the approval to initiate epilepsy study | BioStock: Saniona comments on the approval to initiate epilepsy study
Thu, Sep 19, 2024 10:37 CET Report this content
Saniona has received approval to initiate a phase I multiple ascending dose and biomarker study in adults for SAN711, mark... |
| 02.09.2024 | BioStock: Saniona aiming for new clinical data and first market approval | BioStock: Saniona aiming for new clinical data and first market approval
Mon, Sep 02, 2024 14:42 CET Report this content
In its recently published interim report, Saniona’s CEO Thomas Feldthus highlights the external interest in one of the ... |
| 19.06.2024 | Saniona’s CEO to BioStock: “We have meetings with potential partners every week” | Saniona’s CEO to BioStock: “We have meetings with potential partners every week”
Wed, Jun 19, 2024 09:55 CET Report this content
Saniona is currently advancing its epilepsy assets to provide clinical proof-of-concept for SAN711 and preparin... |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds
In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 28.12.2021 | Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome | PRESS RELEASE
December 28, 2021
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).... |
| 03.12.2021 | Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market | PRESS RELEASE
December 2, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the Chairman and the CEO, as well as additional members of the Board of Directors and executive ... |
| 17.11.2021 | Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity | PRESS RELEASE
November 17, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO). T... |
| 16.09.2021 | Saniona : appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee | PRESS RELEASE
16 September 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of
Robert E. Hoffman to its board of directors, as resolved at the extraordinary sha... |
| 26.08.2021 | Saniona : Interim Report Q2, 2021 | INTERIM REPORT FOR SANIONA AB (PUBL) 556962-5345 January - June 2021
Published August 26, 2021
Saniona Achieves Clinical Progress in Q2 2021 and Subsequent Period, with Orphan Status for Tesomet in HO and Start of Phase 1 for SAN711
Three M... |
| 26.08.2021 | Saniona : 08.26.21 Q2 2021 Report | INTERIM REPORT FOR SANIONA AB (PUBL) 556962-5345 January - June 2021
Published August 26, 2021
Saniona Achieves Clinical Progress in Q2 2021 and Subsequent Period, with Orphan Status for Tesomet in HO and Start of Phase 1 for SAN711
Three M... |
| 20.08.2021 | Saniona : Notice of Saniona AB extraordinary shareholders' meeting to elect new member of the board of directors | PRESS RELEASE
August 20, 2021
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders in Saniona AB, Reg. No. 556962-... |
| 20.08.2021 | Saniona : The Nomination Committee's proposals and reasoned statement | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The Nomination Committee's proposals and reasoned statement for the extraordin... |
| 20.08.2021 | Saniona : Notice of extraordinary shareholders' meeting 2021 | PRESS RELEASE
August 20, 2021
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Notice of Saniona AB extraordinary shareholders'... |
| 14.07.2021 | Saniona : secures SEK 87 million ($10 million) non-dilutive term loan | PRESS RELEASE
July 14, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ($10 million) with Formue... |
| 26.05.2021 | SANIONA AB (PUBL)
Saniona : Interim Report Q1, 2021 | INTERIM REPORT FOR SANIONA AB (PUBL) 556962-5345 January - March 2021
Published May 26, 2021
Saniona Starts Strong in 2021 with Orphan Drug Designation for PWS and Alignment on the Regulatory Path for Tesomet
Q1 2021 (Q1 2020)
Revenue was S... |
| 26.05.2021 | Saniona : Interim Report Q1, 2021 | INTERIM REPORT FOR SANIONA AB (PUBL) 556962-5345 January - March 2021
Published May 26, 2021
Saniona Starts Strong in 2021 with Orphan Drug Designation for PWS and Alignment on the Regulatory Path for Tesomet
Q1 2021 (Q1 2020)
Revenue was S... |
| 22.06.2020 | SANIONA AB (PUBL)
Saniona raises SEK 22 million through sales of shares in Scandion Oncology | PRESS RELEASE
22 June, 2020
Saniona (OMX: SANION), a clinical-stage biotech company focused on rare diseases, today announced that it has raised SEK 22 million (USD 2.3 million) through the sale of shares in Scandion Oncology A/S (Spotlight... |
| - | How do you treat a rare obesity disorder that defies diet and exercise? | Ashley H. Shoemaker, MD, Assistant Professor of Pediatric Endocrinology and Diabetes, Vanderbilt University Medical Center
What if your brain couldn’t register the meals you ate or, despite restricting food intake, you continued to gain wei... |
